CalciMedica Business Summary

CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, primarily generating value through the advancement of its proprietary ion channel technology platform. The company focuses on the discovery and development of first-in-class small molecule inhibitors of calcium release-activated calcium (CRAC) channels to treat acute and chronic inflammatory and immunologic diseases. Its primary business segments are categorized by clinical indications for its lead candidate, Auxora (zegocractin), which include acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), and pulmonary arterial hypertension (PAH). As of March 2026, the company is transitioning toward a pivotal Phase 3 program in AP following the 2026 discontinuation of its Phase 2 KOURAGE trial in acute kidney injury. CalciMedica competes directly with other clinical-stage biotech firms such as Telomir Pharmaceuticals, Celularity, Atossa Genetics, and Generation Bio; it distinguishes itself as a pioneer in the niche CRAC channel inhibition space, targeting intracellular calcium signaling to prevent organ-level inflammation and endothelial damage. The leadership team is anchored by Chief Executive Officer Rachel A. Leheny, Ph.D., a former venture capitalist at Valence Advantage Life Sciences and senior biotechnology analyst at Lehman Brothers and UBS Warburg. The technical foundation is led by Co-founder and Chief Scientific Officer Kenneth A. Stauderman, Ph.D., a preeminent expert in CRAC channel biology with over 30 years of drug discovery experience. Other key executives include Chief Financial Officer Stephen Bardin, previously of atai Life Sciences and Myovant Sciences, and President and COO Michael J. Dunn. The company’s Board of Directors is chaired by Robert N. Wilson, the former Vice Chairman of Johnson & Johnson, and includes notable industry figures such as Fred Middleton, a founding partner of Sanderling Ventures. CalciMedica is supported by a sophisticated institutional investor base that has historically included Deerfield Management, Stonepine Capital Management, and Alyeska Investment Group.